The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Active Pharmaceutical Ingredients (API) CDMO Market Research Report 2025
Synopsis
Active Pharmaceutical Ingredient (API) Contract Development and Manufacturing Organization (CDMO) provides services related to the development, manufacturing, and supply of active pharmaceutical ingredients used in the formulation of pharmaceutical products. API CDMOs play a crucial role in the pharmaceutical industry by assisting pharmaceutical companies in bringing their drug products to market efficiently and cost-effectively.
Global Active Pharmaceutical Ingredients (API) CDMO market is projected to reach US$ 93530 million in 2029, increasing from US$ 53870 million in 2022, with the CAGR of 8.2% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Active Pharmaceutical Ingredients (API) CDMO market research.
The global market for Active Pharmaceutical Ingredients (API) Contract Development and Manufacturing Organization (CDMO) services has experienced significant growth in recent years. API CDMOs play a critical role in the pharmaceutical industry by offering specialized expertise and capabilities in API development and manufacturing. The expanding pharmaceutical sector, driven by an aging population, increasing prevalence of chronic diseases, and advancements in medical treatments, has fueled the demand for API CDMO services. Pharmaceutical companies have increasingly turned to API CDMOs for cost-effective and time-efficient solutions, enabling them to focus on core competencies, research, and commercialization. The United States and Canada are major consumers of API CDMO services due to a large number of pharmaceutical companies and a robust drug development landscape. European countries, including the United Kingdom, Germany, and Switzerland, have a well-established pharmaceutical industry, contributing to significant demand for API CDMO services. Countries like India, China, and South Korea have emerged as major players in the API CDMO market, offering cost-competitive services and a skilled workforce. The global market for API CDMO services is expected to continue its growth trajectory in the coming years. As pharmaceutical companies seek to streamline their drug development processes, reduce costs, and access specialized expertise, API CDMOs will play a pivotal role in supporting the industry. Moreover, as the pharmaceutical landscape continues to evolve with the introduction of innovative therapies and biologics, API CDMOs will likely invest in advanced technologies and expand their service offerings to cater to the evolving needs of pharmaceutical companies.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Active Pharmaceutical Ingredients (API) CDMO market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Recipharm
Cambrex Corporation
Patheon (Thermo Fisher Scientific)
CordenPharma
Lonza
Siegfried
Catalent
Boehringer Ingelheim
Piramal Group
AbbVie
SGS Quay Pharmaceuticals
Aenova Group
Curia
Sterling Pharma Solutions
Eurofins CDMO
Segment by Type
Macromolecular API
Small Molecule API
Segment by Application
Clinical
Commercial
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Active Pharmaceutical Ingredients (API) CDMO report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Active Pharmaceutical Ingredient (API) Contract Development and Manufacturing Organization (CDMO) provides services related to the development, manufacturing, and supply of active pharmaceutical ingredients used in the formulation of pharmaceutical products. API CDMOs play a crucial role in the pharmaceutical industry by assisting pharmaceutical companies in bringing their drug products to market efficiently and cost-effectively.
Global Active Pharmaceutical Ingredients (API) CDMO market is projected to reach US$ 93530 million in 2029, increasing from US$ 53870 million in 2022, with the CAGR of 8.2% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Active Pharmaceutical Ingredients (API) CDMO market research.
The global market for Active Pharmaceutical Ingredients (API) Contract Development and Manufacturing Organization (CDMO) services has experienced significant growth in recent years. API CDMOs play a critical role in the pharmaceutical industry by offering specialized expertise and capabilities in API development and manufacturing. The expanding pharmaceutical sector, driven by an aging population, increasing prevalence of chronic diseases, and advancements in medical treatments, has fueled the demand for API CDMO services. Pharmaceutical companies have increasingly turned to API CDMOs for cost-effective and time-efficient solutions, enabling them to focus on core competencies, research, and commercialization. The United States and Canada are major consumers of API CDMO services due to a large number of pharmaceutical companies and a robust drug development landscape. European countries, including the United Kingdom, Germany, and Switzerland, have a well-established pharmaceutical industry, contributing to significant demand for API CDMO services. Countries like India, China, and South Korea have emerged as major players in the API CDMO market, offering cost-competitive services and a skilled workforce. The global market for API CDMO services is expected to continue its growth trajectory in the coming years. As pharmaceutical companies seek to streamline their drug development processes, reduce costs, and access specialized expertise, API CDMOs will play a pivotal role in supporting the industry. Moreover, as the pharmaceutical landscape continues to evolve with the introduction of innovative therapies and biologics, API CDMOs will likely invest in advanced technologies and expand their service offerings to cater to the evolving needs of pharmaceutical companies.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Active Pharmaceutical Ingredients (API) CDMO market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Recipharm
Cambrex Corporation
Patheon (Thermo Fisher Scientific)
CordenPharma
Lonza
Siegfried
Catalent
Boehringer Ingelheim
Piramal Group
AbbVie
SGS Quay Pharmaceuticals
Aenova Group
Curia
Sterling Pharma Solutions
Eurofins CDMO
Segment by Type
Macromolecular API
Small Molecule API
Segment by Application
Clinical
Commercial
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Active Pharmaceutical Ingredients (API) CDMO report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Active Pharmaceutical Ingredients (API) CDMO Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Macromolecular API
1.2.3 Small Molecule API
1.3 Market by Application
1.3.1 Global Active Pharmaceutical Ingredients (API) CDMO Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Clinical
1.3.3 Commercial
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Active Pharmaceutical Ingredients (API) CDMO Market Perspective (2018-2029)
2.2 Active Pharmaceutical Ingredients (API) CDMO Growth Trends by Region
2.2.1 Global Active Pharmaceutical Ingredients (API) CDMO Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Active Pharmaceutical Ingredients (API) CDMO Historic Market Size by Region (2018-2023)
2.2.3 Active Pharmaceutical Ingredients (API) CDMO Forecasted Market Size by Region (2024-2029)
2.3 Active Pharmaceutical Ingredients (API) CDMO Market Dynamics
2.3.1 Active Pharmaceutical Ingredients (API) CDMO Industry Trends
2.3.2 Active Pharmaceutical Ingredients (API) CDMO Market Drivers
2.3.3 Active Pharmaceutical Ingredients (API) CDMO Market Challenges
2.3.4 Active Pharmaceutical Ingredients (API) CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Active Pharmaceutical Ingredients (API) CDMO Players by Revenue
3.1.1 Global Top Active Pharmaceutical Ingredients (API) CDMO Players by Revenue (2018-2023)
3.1.2 Global Active Pharmaceutical Ingredients (API) CDMO Revenue Market Share by Players (2018-2023)
3.2 Global Active Pharmaceutical Ingredients (API) CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Active Pharmaceutical Ingredients (API) CDMO Revenue
3.4 Global Active Pharmaceutical Ingredients (API) CDMO Market Concentration Ratio
3.4.1 Global Active Pharmaceutical Ingredients (API) CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Active Pharmaceutical Ingredients (API) CDMO Revenue in 2022
3.5 Active Pharmaceutical Ingredients (API) CDMO Key Players Head office and Area Served
3.6 Key Players Active Pharmaceutical Ingredients (API) CDMO Product Solution and Service
3.7 Date of Enter into Active Pharmaceutical Ingredients (API) CDMO Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Active Pharmaceutical Ingredients (API) CDMO Breakdown Data by Type
4.1 Global Active Pharmaceutical Ingredients (API) CDMO Historic Market Size by Type (2018-2023)
4.2 Global Active Pharmaceutical Ingredients (API) CDMO Forecasted Market Size by Type (2024-2029)
5 Active Pharmaceutical Ingredients (API) CDMO Breakdown Data by Application
5.1 Global Active Pharmaceutical Ingredients (API) CDMO Historic Market Size by Application (2018-2023)
5.2 Global Active Pharmaceutical Ingredients (API) CDMO Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Active Pharmaceutical Ingredients (API) CDMO Market Size (2018-2029)
6.2 North America Active Pharmaceutical Ingredients (API) CDMO Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2018-2023)
6.4 North America Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Active Pharmaceutical Ingredients (API) CDMO Market Size (2018-2029)
7.2 Europe Active Pharmaceutical Ingredients (API) CDMO Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2018-2023)
7.4 Europe Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Market Size (2018-2029)
8.2 Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Market Size by Region (2018-2023)
8.4 Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Active Pharmaceutical Ingredients (API) CDMO Market Size (2018-2029)
9.2 Latin America Active Pharmaceutical Ingredients (API) CDMO Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2018-2023)
9.4 Latin America Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Size (2018-2029)
10.2 Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2018-2023)
10.4 Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Recipharm
11.1.1 Recipharm Company Detail
11.1.2 Recipharm Business Overview
11.1.3 Recipharm Active Pharmaceutical Ingredients (API) CDMO Introduction
11.1.4 Recipharm Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023)
11.1.5 Recipharm Recent Development
11.2 Cambrex Corporation
11.2.1 Cambrex Corporation Company Detail
11.2.2 Cambrex Corporation Business Overview
11.2.3 Cambrex Corporation Active Pharmaceutical Ingredients (API) CDMO Introduction
11.2.4 Cambrex Corporation Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023)
11.2.5 Cambrex Corporation Recent Development
11.3 Patheon (Thermo Fisher Scientific)
11.3.1 Patheon (Thermo Fisher Scientific) Company Detail
11.3.2 Patheon (Thermo Fisher Scientific) Business Overview
11.3.3 Patheon (Thermo Fisher Scientific) Active Pharmaceutical Ingredients (API) CDMO Introduction
11.3.4 Patheon (Thermo Fisher Scientific) Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023)
11.3.5 Patheon (Thermo Fisher Scientific) Recent Development
11.4 CordenPharma
11.4.1 CordenPharma Company Detail
11.4.2 CordenPharma Business Overview
11.4.3 CordenPharma Active Pharmaceutical Ingredients (API) CDMO Introduction
11.4.4 CordenPharma Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023)
11.4.5 CordenPharma Recent Development
11.5 Lonza
11.5.1 Lonza Company Detail
11.5.2 Lonza Business Overview
11.5.3 Lonza Active Pharmaceutical Ingredients (API) CDMO Introduction
11.5.4 Lonza Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023)
11.5.5 Lonza Recent Development
11.6 Siegfried
11.6.1 Siegfried Company Detail
11.6.2 Siegfried Business Overview
11.6.3 Siegfried Active Pharmaceutical Ingredients (API) CDMO Introduction
11.6.4 Siegfried Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023)
11.6.5 Siegfried Recent Development
11.7 Catalent
11.7.1 Catalent Company Detail
11.7.2 Catalent Business Overview
11.7.3 Catalent Active Pharmaceutical Ingredients (API) CDMO Introduction
11.7.4 Catalent Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023)
11.7.5 Catalent Recent Development
11.8 Boehringer Ingelheim
11.8.1 Boehringer Ingelheim Company Detail
11.8.2 Boehringer Ingelheim Business Overview
11.8.3 Boehringer Ingelheim Active Pharmaceutical Ingredients (API) CDMO Introduction
11.8.4 Boehringer Ingelheim Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023)
11.8.5 Boehringer Ingelheim Recent Development
11.9 Piramal Group
11.9.1 Piramal Group Company Detail
11.9.2 Piramal Group Business Overview
11.9.3 Piramal Group Active Pharmaceutical Ingredients (API) CDMO Introduction
11.9.4 Piramal Group Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023)
11.9.5 Piramal Group Recent Development
11.10 AbbVie
11.10.1 AbbVie Company Detail
11.10.2 AbbVie Business Overview
11.10.3 AbbVie Active Pharmaceutical Ingredients (API) CDMO Introduction
11.10.4 AbbVie Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023)
11.10.5 AbbVie Recent Development
11.11 SGS Quay Pharmaceuticals
11.11.1 SGS Quay Pharmaceuticals Company Detail
11.11.2 SGS Quay Pharmaceuticals Business Overview
11.11.3 SGS Quay Pharmaceuticals Active Pharmaceutical Ingredients (API) CDMO Introduction
11.11.4 SGS Quay Pharmaceuticals Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023)
11.11.5 SGS Quay Pharmaceuticals Recent Development
11.12 Aenova Group
11.12.1 Aenova Group Company Detail
11.12.2 Aenova Group Business Overview
11.12.3 Aenova Group Active Pharmaceutical Ingredients (API) CDMO Introduction
11.12.4 Aenova Group Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023)
11.12.5 Aenova Group Recent Development
11.13 Curia
11.13.1 Curia Company Detail
11.13.2 Curia Business Overview
11.13.3 Curia Active Pharmaceutical Ingredients (API) CDMO Introduction
11.13.4 Curia Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023)
11.13.5 Curia Recent Development
11.14 Sterling Pharma Solutions
11.14.1 Sterling Pharma Solutions Company Detail
11.14.2 Sterling Pharma Solutions Business Overview
11.14.3 Sterling Pharma Solutions Active Pharmaceutical Ingredients (API) CDMO Introduction
11.14.4 Sterling Pharma Solutions Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023)
11.14.5 Sterling Pharma Solutions Recent Development
11.15 Eurofins CDMO
11.15.1 Eurofins CDMO Company Detail
11.15.2 Eurofins CDMO Business Overview
11.15.3 Eurofins CDMO Active Pharmaceutical Ingredients (API) CDMO Introduction
11.15.4 Eurofins CDMO Revenue in Active Pharmaceutical Ingredients (API) CDMO Business (2018-2023)
11.15.5 Eurofins CDMO Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
